Guidelines and laws intended to regulate the pharmaceutical market are prepared in close co-operation with organisations in Europe and world-wide. The marketing authorisation as well as the monitoring of the quality, efficacy, and safety of medicinal products is an obligation fulfilled at an international level.
Experts of the Paul-Ehrlich-Institut (PEI) are active in bodies and working groups of international organisations:
European Medicines Agency (EMA)
Heads of Medicines Agencies (HMA)
European Directorate for the Quality of Medicines (EDQM)
European Commission (EC)
World Health Organization (WHO)
Global Health Protection Programme (GHPP)
Blood Information System for Crisis Intervention and Management (BISKIT)
Bilateral International Co-operations
Center for the State Control of Drugs and Medical Devices of the Republic of Cuba
Federal Comission for the Protection against Sanitary Risk (COFEPRIS, Mexico)
Food and Drug Administration (FDA, USA)
Food and Drugs Authority Ghana (Ghana FDA)
Health Canada
Health Sciences Authority (HSA, Singapore)
National Institute of Food and Drug Safety Evaluation (NIFDS, South Korea)
National Institutes for Food and Drug Control (NIFDC, China)
Swissmedic (Switzerland)
Therapeutic Goods Administration (TGA, Australia)
Updated: 25.07.2024
